NeuroSense enrolls first patient in mid-stage ALS trial for its combination therapy PrimeC
seekingalpha.com
finance
2022-06-01 14:04:24

chrupka/iStock via Getty Images NeuroSense Therapeutics (NASDAQ:NRSN) on Wednesday said it had enrolled the first patient in its phase 2b trial for its lead drug candidate PrimeC to treat neurodegenerative disease (ALS). NRSN stock +8.5% to $1.53 in morning trade. Amyotrophic lateral sclerosis (ALS) is a progressive nervous system disease that affects the nerve cells in the brain and spinal cord and causes loss of muscle control. NeuroSense's mid-stage ALS trial, called PARADIGM, will enroll 69 people living with the disease in Israel, Italy and the U.
